三甲基胺N-氧化物水平与认知功能障碍之间的关联:系统性审查和元分析
1Department of Anesthesiology, Pengzhou People's Hospital, Pengzhou City, Chengdu, Sichuan Province, China.
PeerJ
|September 12, 2025
概括
升高的三甲基胺N氧化物 (TMAO) 水平与认知功能障碍显著相关. 这一元分析证实了高TMAO和认知功能受损之间的相关性.
科学领域:
- 代谢学 代谢学 代谢学
- 神经科学是一个神经科学.
- 微生物组研究 微生物组研究
背景情况:
- 三甲基胺N氧化物 (TMAO) 是一种肠道微生物代谢物,与各种健康状况有关.
- 以前的研究表明TMAO水平与认知功能障碍之间存在联系,但研究结果不一致.
研究的目的:
- 进行元分析,调查TMAO水平与认知功能障碍之间的关联.
- 为了澄清TMAO和认知障碍之间的关系.
主要方法:
- 在主要数据库 (PubMed,Embase,Scopus,Cochrane,Web of Science) 进行了系统的文献搜索,截至2024年1月25日.
- 包括7项相关研究,共有1675名参与者 (352名认知功能障碍患者,1323名对照患者).
- 使用元分析汇集数据并评估关联.
主要成果:
- 与对照组相比,患有认知功能障碍的患者表现出明显更高的TMAO水平.
- 对TMAO的综合标准平均差异为1.21 (95% CI [0.53-1.89],p=0.0005).
- 观察到很高的异质性 (I2=96%).
结论:
- 提升的TMAO水平与认知功能障碍有显著的相关性.
- TMAO可能作为潜在的认知障碍生物标志物.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
563
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
563
Role of Neurotransmitters in Memory
2.5K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.5K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827


